Long-term effectiveness of the combination of iguratimod and alendronate in SAPHO syndrome: a prospective cohort study
The combination of IGU and Alendronate as initial treatment may be effective for the long-term management of SAPHO syndrome. ∼41% of the patients could discontinue treatment after more than two years without recurrence.
Authors
- Hongji Duan
- Hong Zhao (ORCID: https://orcid.org/0000-0002-8069-9901)
- Lingge Wu
- Xueya Lv
- Wenjie Tang (ORCID: https://orcid.org/0000-0002-9752-4948)
- Xiaoli Deng (ORCID: https://orcid.org/0000-0001-7206-7632)
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Beijing Jishuitan Hospital (CN)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1093/rheumatology/keae641
- Citations
- 2
- Primary Topic
- Osteomyelitis and Bone Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.94